

FORM PTO 1449
(REV 2-32)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

File No. 97-75C1

Serial No.
10/011,859

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

MAR 14 2002 (Use several sheets if necessary)

Applicant(s):

Paul O. Sheppard, Stephen R. Jasper
Zeren Gao

Filing Date:

November 5, 2001

Group:

TECH CENTER 1600/2900

MAR 21 2002

RECEIVED

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
<i>JS</i>	A1	99/21998	5/6/99	PCT		

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Patents, etc.)

<i>JS</i>	A2	LIFESEQ™ Clone Information Results (INC555067), Incyte Pharmaceuticals, Inc., 1995.
	A3	LIFESEQ™ Clone Information Results (INC2509339), Incyte Pharmaceuticals, Inc., 1997.
	A4	LIFESEQ™ Clone Information Results (INC3208053), Incyte Pharmaceuticals, Inc., 1997.
	A5	LIFESEQ™ Clone Information Results (INC3941821), Incyte Pharmaceuticals, Inc., 1997.
	A6	LIFESEQ™ Clone Information Results (INC3036490), Incyte Pharmaceuticals, Inc., 1998.
	A7	Strausberg, Cancer Genome Anatomy Project, Genbank Acc. No. AA592984, 1997.
	A8	Strausberg, Cancer Genome Anatomy Project, Genbank Acc. No. AA897322, 1997.
	A9	Marra et al., WashU-HHMI Mouse EST Project, Genbank Acc. No. AA200958, 1996.
	A10	Marra et al., WashU-HHMI Mouse EST Project, Genbank Acc. No. AA764003, 1996.
	A11	Marra et al., WashU-HHMI Mouse EST Project, Genbank Acc. No. AA840452, 1996.
	A12	LIFESEQ™ Library Information Results (BRAIUNT01), Incyte Pharmaceuticals, Inc., date unknown.
	A13	LIFESEQ™ Library Information Results (SCORNOT04), Incyte Pharmaceuticals, Inc., date unknown.

Examiner

J. Spector

Date considered

1/5/05

EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[illegible]

RECEIVED

MAR 21 2002

1-800-271-1690/290

P.T.O. 1449
(REV. 2-32)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

File No. 97-75C1

Serial No.
10/011,859SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

(Use several sheets if necessary)

Applicant(s):
Paul O. Sheppard, Stephen R. Jaspers,
Zeren GaoFiling Date:
November 5, 2001

Group: 1647

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	Name	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
A ↓	5,194,596	3/16/93	Tischer et al.	530	399	
	5,350,836	9/27/94	Kopchick et al.	530	399	
	5,408,040	4/18/95	Grotendorst et al.	530	399	

FOREIGN PATENT DOCUMENTS

Examiner Initial	DOCUMENT NUMBER	Date	COUNTRY	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE


OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Patents, etc.)

A ↓		A. Gladwin et al., <i>Human Molecular Genetics</i> 6(1):123-127, 1997.
		N. Braveman et al., <i>Nature Genetics</i> 15:369-376, 1997.
		C.C. Pilbeam et al., "Comparison of the effects of various lengths of synthetic human parathyroid hormone-related peptide (hPTHrP) or malignancy on bone resorption and formation in organ culture," <i>Bone</i> 14:717-720, 1993.
		S. Vukicevic et al., "Induction of nephrogenic mesenchyme by osteogenic protein 1 (bone morphogenetic protein 7)," <i>Proc. Nat. Acad. Sci. USA</i> 93:9021-9026, 1996.
		J. Massague, "The TGF- β family of growth and differentiation factors," <i>Cell</i> 49:437-438, 1987.
		L.E. Benjamin et al., "A plasticity window for blood vessel remodeling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF," <i>Development</i> 125:
		J. Skoinick et al., "From genes to protein structure and function: novel applications of computational approaches in the genomic era," <i>Trends in Biotech</i> 18(1):34-39, 2000.
		P. Bork, "Powers and pitfalls in sequence analysis: The 70% hurdle," <i>Genome Research</i> 10:398-400, 2000.

Examiner

Date considered

EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		File No. 97-75C1	Serial No. 10/011,859
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant(s): Paul O. Sheppard, Stephen R. Jaspers, Zeren Gao	
		Filing Date: November 5, 2001	Group: 1647

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	Name	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

Examiner Initial	DOCUMENT NUMBER	Date	COUNTRY	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Patents, etc.)

		T. Doerks et al., "Protein annotation: detective work for function prediction," <i>Trends in Genetics</i> 4(g):248-250, June 1998.
		T.F. Smith et al., "The challenges of genome sequence annotation or "The devil is in the details," <i>Nature Biotechnology</i> 15:1222-1223, 1997.
		S.E. Brenner, "Erros in genome annotation," <i>Trends in Genetics</i> 15(4):132-133, 1999.
		P. Bork, "Go hunting in sequence databases but watch out for the traps," <i>Trends in Genetics</i> 12(10):425-426, 1996.
		R. Strausberg, Loci AW592899 and AA592984, 1997, National Cancer Institute Cancer Genome Anatomy Project, Tumor Gene Index, Accessed 8/21/00

Examiner	Date considered 1/5/05
----------	---------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.